Отправить эту статью по почте 
ПИРИБЕДИЛ: ПОКАЗАНИЯ ДЛЯ НАЗНАЧЕНИЯ В ПСИХИАТРИИ И НАРКОЛОГИИ
Аннотация
Цель исследования. Представить читателю данные о рецепторном профиле и спектре фармакологической активности пирибедила (исторически первого не эрголинового агониста D2 и D3 подтипов дофаминовых рецепторов), о механизмах его терапевтического эффекта, о показаниях к его применению в психиатрии и наркологии (т.е., за пределами изначального его показания в неврологии при лечении болезни Паркинсона), и о доказательной базе для его применения при различных психических и наркологических расстройствах.
Методология проведения работы. Мы провели поиск и изучение литературных данных о пирибедиле в поисковых системах и базах данных PubMed, Google Scholar, Science Direct, Ki Database, с использованием соответствующих ключевых слов.
Результаты. Найденные нами в ходе составления настоящего обзора литературные данные свидетельствуют о том, что пирибедил может обладать, помимо антипаркинсонических свойств, также антидементным, прокогнитивным (ноотропным), антиамнестическим, антидепрессивным, анксиолитическим, анальгетическим, сосудорасширяющим (особенно в отношении церебральных сосудов) эффектами. Он также способен снижать секрецию пролактина и ряда других стрессовых гормонов. Эти свойства пирибедила могут обуславливать его эффективность в составе комплексной терапии различных форм деменций, лёгких и умеренных когнитивных нарушений, депрессивных и тревожных расстройств, синдрома дефицита внимания и гиперактивности, соматоформных и других хронических болевых расстройств, синдрома деперсонализации-дереализации, а также в качестве корректора побочных эффектов антипсихотиков и средства, уменьшающего негативную симптоматику, при лечении шизофрении и расстройств шизофренического спектра.
Область применения результатов. Результаты этого обзора заслуживают самого широкого применения в психиатрии, наркологии и неврологии.
Ключевые слова
Полный текст:
>PDF
Литература
Stahl S.M. Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 4th Ed. Cambridge University Press, 2013. ISBN 978-1107686465
Illarioshkin S.N., Karpova E.A., Ivanova-Smolenskaya I.A., Chernikova L.A. Agonist dofaminovyh retseptorov piribedil v lechenii bolezni Parkinsona [An agonist of dopamine receptors piribedil in the treatment of Parkinson disease]. Nevrologija i revmatologija. Prilozhenie k zhurnalu Consilium Medicum, 2013, no. 1, pp. 25-29.
Perez-Lloret S., Rascol O. Piribedil for the Treatment of Motor and Non-motor Symptoms of Parkinson Disease. CNS Drugs, 2016, vol. 8, no. 30, pp. 703-717. doi: 10.1007/s40263-016-0360-5
Mittur A. Piribedil: Antiparkinsonian Properties and Potential Clinical Utility in Dopaminergic Disorders. Current Drug Therapy, 2011, vol. 6, no. 1, pp.17-34.
Suwantamee J., Nidhinandana S., Srisuwananukorn S., Laptikultham S., Pisarnpong A., Chankrachang S., Bundhukul A. Efficacy and safety of piribedil in early combination with L-dopa in the treatment of Parkinson’s disease: a 6-month open study. J Med Assoc Thai, 2004, vol. 11, no. 87, pp. 1293-1300.
Millan M.J., Cussac D., Milligan G., Carr C., Audinot V., Gobert A., Lejeune F., Rivet J.M., Brocco M., Duqueyroix D. Antiparkinsonian agent piribedil displays antagonist properties at native, rat, and cloned, human alpha(2)-adrenoceptors: cellular and functional characterization. J Pharmacol Exp Ther, 2001, vol. 3, no. 297, pp. 876-887.
Pilipovich A.A., Golubev V.L. Primenenie pronorana v nevrologicheskoj praktike [The use of pronoran in the neurological practice]. Lechenie zabolevanij nervnoj sistemy, 2009, no. 1, pp. 14-20.
Cagnotto A., Parotti L., Mennini T. In vitro affinity of piribedil for dopamine D3 receptor subtypes, an autoradiographic study. Eur J Pharmacol, 1996, vol. 10, pp. 63-67. doi: 10.1016/0014-2999(96)00503-1
Millan M.J., Maiofiss L., Cussac D., Audinot V., Boutin J.A., Newman-Tancredi A. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther, 2002, vol. 2, no. 303, pp. 791-804. doi: 10.1124/jpet.102.039867
Simon N., Micallef J., Reynier J.C., Lesourd M., Witjas T., Alicherif A., Azulay J.P., Blin O. End-of-dose akinesia after a single intravenous infusion of the dopaminergic agonist piribedil in Parkinson’s disease patients: a pharmacokinetic/pharmacodynamic, randomized, double-blind study. Mov Disord, 2005, vol. 7, no. 20, pp. 803-809. doi: 10.1002/mds.20400
Bykov Yu.V., Bekker R.A. Ariprizol – unikal’nyj antipsikhotik s schirokim spektrom primenenija v psikhiatrii: fakty i perspektivy [Ariprizol: an unique antipsychotic with a wide spectrum of usability in psychiatry]. Psikhiatrija i psikhofarmakoterapija im. P.B. Gannushkina, 2017, no. 4, pp. 30-47.
Pizova N.V. Pronoran v lechenii kognitivnyh rasstrojstv [Pronoran in the treatment of cognitive disorders]. Consilium Medicum, 2008, no. 12, pp. 65-70.
Bykov Yu.V., Bekker R.A. Proroksan v narkologii i psikhiatrii (chast’ 1) [Proroxan in addiction medicine and psychiatry (Part 1)]. Psikhiatrija i psikhofarmakoterapija im. P.B. Gannushkina, 2017, no. 2, pp. 44-51.
Bykov Yu.V., Bekker R.A. Khlorprotiksen: obzor primenenija v psikhiatrii (I chast’) [Chlorprothixene: a review of its use in psychiatry]. Psikhiatrija i psikhofarmakoterapija im. P.B. Gannushkina, 2016, no. 2, pp. 26-32.
Fedorova N.V., Artemjeva E.G. Primenenie pronorana – sovremennogo agonista dofaminovyh retseptorov v lechenii bolezni Parkinsona [The use of pronoran – a modern agonist of dopamine receptors in the treatment of Parkinson disease]. Informatsionnoe pis’mo, Moscow, 2003.
Fedorova N.V., Kim I.P. Lechenie bolezni Parkinsona [The treatment of Parkinson disease]. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova, 2002, no. 2, pp. 68-75.
Ziegler M., Rondot P. Activity of piribedil in Parkinson’s disease: a multicenter study. Presse Med, 1999, no. 28, pp. 1414-1418.
Calzi F., Bellasio R., Guiso G., Caccia S., Tacconiet M.T. Effect of piribedil and its metabolite, S584, on brain lipid peroxidation in vitro and in vivo. Eur J Pharmacol, 1997, vol. 2, no. 338, pp. 185-190. doi: 10.1016/s0014-2999(97)81947-4
Joffe R.T., Post R.M., Ballenger J.C., Rebar R., Rakita R., Gold P.W. Neuroendocrine effects of the dopamine agonist piribedil in depressed patients. Clin Neuropharmacol, 1986, vol. 5, no. 9, pp. 448-455. doi: 10.1097/00002826-198610000-00005.
Diehl D.J., Gershon S. The role of dopamine in mood disorders. Compr Psychiatry, 1992, vol. 2, no. 33, pp. 115-120. doi: 10.1016/0010-440x(92)90007-d
Levin O.S., Golubeva L.V. Geterogennost’ umerennogo kognitivnogo rasstrojstva: diagnosticheskie i terapevticheskie aspekty [Heterogeneity of mild cognitive impairment: diagnostic and therapeutic aspects]. Consilium Medicum, 2006, no. 2, pp. 106-112.
Jonker C., Geerlings M.I., Schmand B. Are memory predictive for dementia? A review of clinical and population-based studies. Int J Geriatr Psychiatry, 2000, no. 15, pp. 983-991. doi: 10.1002/1099-1166(200011)15:11<983::aid-gps238>3.0.co;2-5.
Venisse T., Montastruc L., Rascal A. Clinical pharmacology and treatment of Parkinson’s disease. Rev Geriat, 1985, no. 10, p. 103.
Velho-Gronberg P., Paal G., Grossmann W. Parkinson tremor: clinical and electrophysiological assessments of the response to piribedil. Psychol Med (Paris), 1979, no. 11, p. 235.
Ziegler M., Rascol O. Efficacy of piribedil in adjunction to L-dopa in a 6-month randomized placebo-controlled study in early Parkinson’s diseases. 52nd Annual Meeting of the American Academy of Neurology. San Diego, 2000; Abstract.
Allain H., Coz F., Del Signore S. Piribedil Plasma Levels after Chronic Oral Administration of Trivastal Retard 50 (150 mg/day) in Parkinsonian Patients. Parkinsonism and related disorders, 2001, vol. 7, p. 51.
Ziegler M., Del Signore S., Bonhomme C. Resting Tremor is Inversely Related to Piribedil Plasma Concentration after Intravenous Administration in Parkinsonian Patients. Parkinsonism and related disorders, 2001, no. 7, p. 75.
Agnoli A., Baldassarini M., Del Roscio C. Piribedil and Parkinson’s disease: Protection of Peripheral Side-Effects by Domperidone. Clin Pharmacol, 1981, no. 2, pp. 117-122.
Shopsin B., Gershon S. Dopamine receptor stimulation in the treatment of depression: piribedil (ET-495). Neuropsychobiology, 1978, vol. 1, no. 4, pp.1-14. doi: 10.1159/000117615
American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry, 2002, vol. 4, no. 159, pp. 1-50.
Post R.M., Gerner R.H., Carman J.S., Gillin J.C., Jimerson D.C., Goodwin F.K., Bunney Jr. W.E. Effects of a dopamine agonist piribedil in depressed patients: relationship of pretreatment homovanillic acid to antidepressant response. Arch Gen Psychiatry, 1978, vol. 5, no. 35, pp. 609-615. doi: 10.1001/archpsyc.1978.01770290091008
Guillaume R., Charles G., Mesters P., Schittecatte M., Wilmotteet J. Stimulation of somatotropin hormone by piribedil, a dopaminergic agonist, in endogenous depression. Preliminary study. Acta Psychiatr Belg, 1988, vol. 2, no. 88, pp. 153-161.
Brocco M., Dekeyne A., Papp M., Millan M.J. Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors. Behav Pharmacol, 2006, vol. 7, no. 17, pp. 559-572. doi: 10.1097/01.fbp.0000236267.41806.5b
Mazo G.E., Neznanov N.G. Terapevticheski rezistentnye depressii [Treatment resistant depressions]. St. Petersburg, 2012, 448 p. ISBN 978-5-905225-48-2
Bykov Yu.V., Bekker R.A., Reznikov M.K. Depressii i rezistentnost’. Prakticheskoe rukovodstvo dlja vrachej [Depressions and resistance. A practical guide for doctors]. Moscow, RIOR: INFRA-M, 2013, 374 p. ISBN 978-5-369-01096-9
Kondo S., Hayashi H., Eguchi T., Oyama T., Wada T., Otani K. Bromocriptine augmentation therapy in a patient with Cotard’s syndrome. Prog Neuropsychopharmacol Biol Psychiatry, 2003, vol. 4, no. 27, pp. 719-721. doi: 10.1016/S0278-5846(03)00083-6
Takahashi T., Nibuya M., Nomura S. Delusion of Cotard’s syndrome successfully treated with a dopamine agonist. J Neuropsychiatry Clin Neurosci, 2010, vol. 2, no. 22, p. E27. doi: 10.1176/jnp.2010.22.2.247.e27.
Maruo J., Haraguchi Y., Tateishi H., Noguchi T., Mizoguchi Y., Kato T. A., Kawashima T., Monji M. Abnormal behaviours during pramipexole treatment for Cotard’s syndrome: a case report. Psychogeriatrics, 2016, vol. 4, no. 16, pp. 283-286. doi: 10.1111/psyg.12148
Pilipovich A.A. Effektivnost’ pronorana u patsientov s boleznju Parkinsona [Efficacy of pronoran in the treatment of Parkinson disease]. Consilium Medicum, 2014, no. 9, pp. 5-10.
Pilipovich A.A. Narushenija pamjati i rol’ pronorana v ih korrektsii [Memory impairments and the role of pronoran in their correction]. Effektivnaja farmakoterapija, 2016, no. 9, pp. 8-17.
Zakharov V.V. Vserossijskaja programma issledovanij epidemiologii i terapii kognitivnyh rasstrojstv v pozhilom vozraste («Prometej») [A Russian national programme on the research of the epidemiology and therapy of cognitive disorders in an advanced age]. Nevrologicheskij zhurnal, 2006, no. 2, pp. 27-32.
Yakhno N.N., Zakharov V.V., Strachunskaja E.Ya. Lechenie nedementnyh kognitivnyh narushenij u patsientov s arterial’noj gipertenziej i tserebral’nym aterosklerozom. (Po rezul’tatam rossijskogo multitsentrovogo issledovanija FUETE.) [The treatment of non-dementing mild cognitive impairment in patients with arterial hypertension and cerebral atherosclerosis]. Nevrologicheskij zhurnal, 2012, no. 4, pp. 49-55.
Ollat H. Dopaminergic insufficiency reflecting cerebral ageing: value of a dopaminergic agonist, piribedil. J Neurol, 1992, vol. 1, no. 239, pp. S13-S16. doi: 10.1007/BF00819561
Nagaraja D., Jayashree S. Randomized study of the dopamine receptor agonist piribedil in the treatment of mild cognitive impairment. Am J Psychiatry, 2001, vol. 9, no. 158, pp. 1517-1519. doi: 10.1176/appi.ajp.158.9.1517
Pirozzolo F.J., Hansch E.C., Mortimer J.A., Webster D.D., Kuskowski M.A. Dementia in Parkinson’s diseases: a neuropsychological analysis. Brain Cogn, 1982, vol. 1, pp. 71-83. doi: 10.1016/0278-2626(82)90007-0
Tandberg E., Larsen J.P., Karlsen K. Excessive daytime sleepiness and sleep benefit in Parkinson’s diseases: community based study. Mov Disord, 1999, no. 14, pp. 71-83. doi: 10.1002/1531-8257(199911)14:6<922::aid-mds1003>3.0.co;2-7
Zakharov V.V. Ispol’zovanie pronorana v lechenii nedementnyh kognitivnyh narushenij [The use of pronoran in the treatment of non-dementing mild cognitive impairment]. Nevrologicheskij zhurnal, 2008, no. 2, pp. 38-42.
Schück S., Bentué-Ferrer D., Kleinermans D., Reymann J.M., Polard E., Gandon J.M., Allain H. Psychomotor and cognitive effects of piribedil, a dopamine agonist, in young healthy volunteers. Fundam Clin Pharmacol, 2002, vol. 1, no. 16, pp. 57-65. doi: 10.1046/j.1472-8206.2002.00070.x
Kahvecioglu U., Özkaynak S., Zadikoglu A. Efficacy of piribedil on age-related cognitive decline. Med J Akdeniz University, 1995, vol. 12, no. 1-3, pp. 1300-1779.
Pilipovich A.A. Bioelektricheskaja aktivnost’ golovnogo mozga u patsientov s boleznju Parkinsona [Bioelectrical activity of the brain in patients with Parkinson disease]. Vrach, 2012, no. 4, pp. 107-112.
Mikhaĭlova N.M., Sokolova O.N., Gavrilova S.I. Pronoran in the treatment of mental organic syndrome in the elderly. Zh Nevrol Psikhiatr Im S S Korsakova, 2004, vol. 10, no. 104, pp. 41-47.
Gavrilova S.I., Selezneva N.D., Zharikov G.A. Pronoran (piribedil) v lechenii sindroma mjagkogo kognitivnogo snizhenija [Pronoran (piribedil) in the treatment of mild cognitive impairment syndrome]. Psikhiatrija, 2005, no. 3, pp. 66-72.
Avedisova A.S., Bochkarev V.K., Faizulloev A.Z. Effektivnost’ pronorana pri vozrastnom uhudshenii pamjati [Efficacy of pronoran in age-related memory decline]. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova, 2005, no. 2, pp. 46-50.
Chernjavskaja T.K. Opyt ispol’zovanija Pronorana dlja povyshenija effektivnosti interaktivnogo obuchenija patsientov pozhilogo vozrasta s arterial’noi gipertoniej i kognitivnymi rasstroistvami [Our experience with the use of Pronoran in patients of advanced age with arterial hypertension and cognitive impairments for improving the effectiveness of their interactive training]. Psikhicheskie rasstrojstva v obshej meditsine, 2009, no. 3, pp. 52-55.
Popova A.A., Alekhina O.D., Burlachuk V.T. Vozmozhnosti korrektsii umerennyh kognitivnyh rasstrojstv u patsientov pozhilogo i starcheskogo vozrasta v obshemeditsinskoj praktike [On the possibilities of treatment of moderate cognitive impairments in patients of advanced and old age in general medical practice]. Psikhicheskie rasstrojstva v obshej meditsine, 2010, no. 2, pp. 49-52.
Shishkova V., Osychenko M. Profilaktika metabolicheskih i kognitivnyh narushenij pri ozhirenii i saharnom diabete tipa 2 [Prophylaxis of metabolic and cognitive impairments in obesity and type 2 diabetes mellitus]. Vrach, 2011, no. 2, pp. 31-34.
Petrova M.M., Prokopenko S.V., Eremina O.V. Osobennosti primenenija piribedila v lechenii kognitivnyh narushenij u patsientov s ishemicheskoj bolezn’u serdtsa [On the peculiarities of the use of piribedil in the treatment of cognitive impairments in patients with an ischemic heart disease]. Klinicheskaja meditsina, 2017, no. 5, pp. 445-450.
Benkert O., Müller-Siecheneder F., Wetzel H. Dopamine agonists in schizophrenia: a review. Eur Neuropsychopharmacol, 1995, vol. 1, no. 5, pp. 43-53. doi: 10.1016/0924-977x(95)00022-h
Bykov Yu.V., Bekker R.A. Sul’pirid v terapii trevozhnyh rasstrojstv i trevozhnoj simptomatiki v ramkah inyh rasstrojstv (obzor literatury) [Sulpiride in the treatment of anxiety disorders and anxiety symptoms in other disorders (a literature review)]. Psikhiatrija i psikhofarmakoterapija im. P.B. Gannushkina, 2016, no. 5, pp. 25-33.
Bekker R.A., Bykov Yu.V. Effektivnost’ amisulprida v terapii depressivnyh narushenij pri shizofrenii i drugih endogennyh psikhozah [Effectiveness of amisulpride in the treatment of depressive symptoms in schizophrenia and other endogenous psychoses]. Psikhiatrija i psikhofarmakoterapija im. P.B. Gannushkina, 2016, no. 3, pp. 19-26.
Kasper S., Barnas C., Heiden A., Volz H.P., Laakmann G., Zeit H., Pfolz H. Pramipexole as adjunct to haloperidol in schizophrenia. Safety and efficacy. Eur Neuropsychopharmacol, 1997, vol. 1, no. 7, pp. 65-70. doi: 10.1016/s0924-977x(96)00393-8
Ishitobi M., Kosaka H., Shukunami K., Murata T., Wadaet Y. Adjunctive treatment with low-dosage pramipexole for risperidone-associated hyperprolactinemia and sexual dysfunction in a male patient with schizophrenia. J Clin Psychopharmacol, 2011, vol. 2, no. 31, pp. 243-245. doi: 10.1097/JCP.0b013e31820f4fbd
Kelleher J.P., Centorrino F., Huxley N.A., Bates J.A., Drake J.K., Egli S., Baldessarini R.J. Pilot randomized, controlled trial of pramipexole to augment antipsychotic treatment. Eur Neuropsychopharmacol, 2012, vol. 6, no. 22, pp. 415-418. doi: 10.1016/j.euroneuro.2011.10.002
Pich E.M., Collo G. Pharmacological targeting of dopamine D3 receptors: Possible clinical applications of selective drugs. Eur Neuropsychopharmacol, 2015, vol. 9, no. 25, pp. 1437-1447. doi: 10.1016/j.euroneuro.2015.07.012
Wood P.B. Role of central dopamine in pain and analgesia. Expert Rev Neurother, 2008, vol. 5, no. 8, pp. 781-797. doi: 10.1586/14737175.8.5.781
Kandre D., Banwari G., Sharma P. Comorbid Functional Shoulder Pain and Zolpidem Dependence Treated with Pramipexole. Indian J Psychol Med, 2015, vol. 4, no. 37, pp. 443-445. doi: 10.4103/0253-7176.168591
Evidente V.G. Piribedil for restless legs syndrome: a pilot study. Mov Disord, 2001, vol. 3, no. 16, pp. 579-581. doi: 10.1002/mds.1104
Sethy V.H., Ellerbrock B.R., Wu H. U-95666E: a potential anti-parkinsonian drug with anxiolytic activity. Prog Neuropsychopharmacol Biol Psychiatry, 1997, vol. 5, no. 21, pp. 873-883. doi: 10.1016/s0278-5846(97)00086-9
Bartoszyk G.D. Anxiolytic effects of dopamine receptor ligands: I. Involvement of dopamine autoreceptors. Life Sci, 1998, vol. 7, no. 62, pp. 649-663. doi: 10.1016/s0024-3205(97)01160-0
Moraga-Amaro R., Gonzalez H., Pacheco R., Stehberg J. Dopamine receptor D3 deficiency results in chronic depression and anxiety. Behav Brain Res, 2014, no. 274, pp. 186-193. doi: 10.1016/j.bbr.2014.07.055
Hood S.D., Potokar J.P., Davies S.J., Hince D.A., Morris K., Seddon K. M., Nutt D.J., Argyropoulos S.V. Dopaminergic challenges in social anxiety disorder: evidence for dopamine D3 desensitisation following successful treatment with serotonergic antidepressants. J Psychopharmacol, 2010, vol. 5, no. 24, pp. 709-716. doi: 10.1177/0269881108098144
Marazziti D., Presta S., Pfanner C., Dell’Osso L., Cassano G.B. Pramipexole augmentation in panic with agoraphobia. Am J Psychiatry, 2001, vol. 3, no. 158, pp. 498-499. doi: 10.1176/appi.ajp.158.3.498-a
Holman A.J., Myers R.R. A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications. Arthritis Rheum, 2005, vol. 8, no. 52, pp. 2495-2505. doi: 10.1002/art.21191
Akhmadeeva G.N., Magzhanov R.V., Tayupova G.N., Bajtimerov A.R., Hidijatova I.M. Anxiety and depressive disorders in Parkinson’s disease. Zh Nevrol Psikhiatr Im S S Korsakova, 2017, vol. 2, no. 117, pp. 54-58. doi: 10.17116/jnevro20171171254-58
Herceg M., Nagy F., Pál E., Janszky J., Késmárky I., Komoly S., Kovács N. Pramipexole may be an effective treatment option in essential tremor. Clin Neuropharmacol, 2012, vol. 2, no. 35, pp. 73-76. doi: 10.1097/WNF.0b013e31824687bf
Ferini-Strambi L., Marelli S. Pharmacotherapy for restless legs syndrome. Expert Opin Pharmacother, 2014, vol. 8, no. 15, pp. 1127-1138. doi: 10.1517/14656566.2014.908850
Lemke M.R. Antidepressant effects of dopamine agonists. Experimental and clinical findings. Nervenarzt, 2007, vol. 1, no. 78, pp. 31-38. doi: 10.1007/s00115-006-2104-0
Sierra M. Depersonalization: A New Look at a Neglected Syndrome. Cambridge University Press. 1st Ed. 2012. ISBN 978-1107406391. 184 p.
Nuller Yu.L. Depressija i depersonalizatsija [Depression and depersonalization]. Leningrad, Meditsina, 1981, 207 p.
Hollander E., Liebowitz M.R., DeCaria C., Fairbanks J., Fallon B., Klein D.F. Treatment of depersonalization with serotonin reuptake blockers. J Clin Psychopharmacol, 1990, vol. 3, no. 10, pp. 200-203.
Bykov Yu.V., Bekker R.A. Anafranil (klomipramin): novyj vzgljad na izvestnyi preparat [Anafranil (clomipramine): a new look on an old drug]. Psikhiatrija i psikhofarmakoterapija im. P.B. Gannushkina, 2020, no. 2, pp. 41-50.
Bout A., Berhili N., Benbrahim M., Aalouane R., Rammouz I. Lamotrigine in the treatment of resistant depersonalization disorder: A case report. Encephale, 2018, vol. 1, no. 44, pp, 85-87. doi: 10.1016/j.encep.2017.04.003
Bekker R.A., Bykov Yu.V. Memantin: vozmozhnosti i perspektivy primenenija v psikhiatrii (obzor sovremennyh dannyh) [Memantine: possibilities and perspectives for its use in psychiatry (a review of modern scientific data)]. Psikhiatrija i psikhofarmakoterapija im. P.B. Gannushkina, 2016, no. 4, pp. 42-51.
Bekker R.A., Bykov Yu.V. Memantin v zhidkoj forme pri nejrodegenerativnyh zabolevanijah: fakty i perspektivy [Memantine oral drops in neurodegenerative disorders: facts and perspectives]. Psikhiatrija i psikhofarmakoterapija im. P.B. Gannushkina, 2020, no. 2, pp. 30-37.
Abbas S., Chandra P.S., Srivastava M. The use of fluoxetine and buspirone for treatment-refractory depersonalization disorder. J Clin Psychiatry, 1995, vol. 10. no. 56, p. 484.
Foguet Q., Alvárez M.J., Castells E., Arrufat F. Methylphenidate in depersonalization disorder: a case report. Actas Esp Psiquiatr, 2011, vol. 1, no. 39, pp. 75-78.
Scarella T.M., Franzen J.R. Case report: Improvement in dissociative symptoms with mixed amphetamine salts. J Trauma Dissociation, 2017, vol. 5, no. 18, pp. 649-662. doi: 10.1080/15299732.2016.1259195
Kosten T.R., George T.P., Kosten T.A. The potential of dopamine agonists in drug addiction. Expert Opin Investig Drugs, 2002, vol. 4, no. 11, pp. 491-499. doi: 10.1517/13543784.11.4.491
Dourish C.T., Cooper S.J. Suppression of drinking and induction of sedation by a dopamine agonist is blocked by small doses of spiperone. Neuropharmacology, 1982, vol. 1, no. 21, pp. 69-72. doi: 10.1016/0028-3908(82)90213-1
DOI: https://doi.org/10.12731/2658-6649-2020-12-4-38-83
Ссылки
- На текущий момент ссылки отсутствуют.
(c) 2020 Yuriy Vitalievich Bykov, Roman Alexandrovich Bekker
Это произведение доступно по лицензии Creative Commons «Attribution-NonCommercial-NoDerivatives» («Атрибуция — Некоммерческое использование — Без производных произведений») 4.0 Всемирная.
ISSN 2658-6649 (print)
ISSN 2658-6657 (online)